SPRY
ARS Pharmaceuticals, Inc
4.20$
-7.2%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -6.2% | -2.4% | -2.5% | -2.0% | +61.4% | -6.8% | -4.2% | +18.9% | -12.1% | -12.2% | -13.2% | |
| – | -5.3% | -2.3% | -2.4% | -5.4% | +60.1% | -9.1% | -7.4% | +20.4% | -15.9% | -13.9% | -13.8% | |
| – | +17.2% | -21.1% | -34.6% | +8.3% | +28.1% | -21.6% | +29.3% | +15.6% | -30.6% | -41.1% | -66.4% | |
| – | -5.6% | -2.1% | -2.2% | -6.5% | +53.5% | -12.2% | -12.9% | +20.0% | -15.0% | -18.0% | -28.4% | |
| – | -2.3% | -22.3% | -12.3% | +128.6% | +639.5% | +12.1% | +153.9% | +44.5% | -30.1% | +11.8% | +59.0% | |
| – | – | – | – | – | +629.0% | +39.5% | +20.2% | -10.9% | +7.5% | +5.4% | +32.6% | |
| – | -10.6% | -14.4% | -15.5% | +1,666.1% | -2.4% | -2.5% | +75.7% | +11.9% | -1.9% | -1.9% | -1.9% | |
| – | -78.5% | +53.0% | +81.0% | +147.2% | +467.6% | +4.2% | +23.2% | +85.8% | -5.2% | +6.0% | +4.7% | |
| – | -78.6% | +55.4% | +81.0% | +147.2% | +41.0% | +17.8% | +65.1% | +11.6% | -23.1% | +26.7% | +22.7% | |
| – | +0.9% | -8.4% | -26.3% | -36.3% | -58.8% | +73.8% | +706.8% | -1.0% | +0.9% | +0.7% | – | |
| – | -74.4% | +10.5% | +290.0% | +152.9% | +19.3% | -58.5% | +280.0% | -46.1% | -31.7% | -17.8% | +1,169.5% | |
| – | – | – | – | – | – | – | – | – | +0.2% | +0.2% | +0.2% | |
| – | -2.7% | -3.0% | -3.9% | -6.6% | +27.8% | -10.8% | -16.0% | -23.2% | -22.6% | -46.3% | -79.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.6% | +0.4% | +0.4% | +0.2% | +1.0% | +0.1% | +0.3% | +0.5% | -0.2% | +0.7% | +0.0% |
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.